The Dominantly Inherited Alzheimer Network (DIAN), Core B: Clinical is responsible for the protocol development of all clinical operations for the research studies, including participant recruitment, enrollment and protection;performing clinical evaluations including neuropsychometric testing, completing imaging, blood and CSF collections, and offering genetic counseling and testing. The study of dominantly inherited Alzheimer Disease will likely lead to a better understanding of the causes of Alzheimer Disease and potential methods of detecting it at the earliest stages, even before clinical symptoms have begun. This will allow for preventative treatments to be tested. The clinical core will obtain highly sensitive clinical evaluations and neuropsychometric testing to determine the earliest symptoms and progression rates. The clinical core will also obtain imaging studies, blood and cerebral-spinal fluid to measure biomarker changes which may occur before symptoms. The data generated from these studies will be used by DIAN investigators to advance the understanding of the causes of Alzheimer Disease, methods of early detection, and design future preventative treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AG032438-06
Application #
8600216
Study Section
Special Emphasis Panel (ZAG1-ZIJ-1)
Project Start
Project End
2014-06-30
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
6
Fiscal Year
2014
Total Cost
$165,294
Indirect Cost
$57,652
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Ringman, John M; Casado, Maria; Van Berlo, Victoria et al. (2017) A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neurosci Lett 657:11-15
Müller, Stephan; Preische, Oliver; Sohrabi, Hamid R et al. (2017) Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Sci Rep 7:1225
Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2017) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13:8-19
Su, Yi; Vlassenko, Andrei G; Couture, Lars E et al. (2017) Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. J Cereb Blood Flow Metab 37:1435-1446
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2017) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement :
Natelson Love, Marissa; Clark, David G; Cochran, J Nicholas et al. (2017) Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiol Aging 49:216.e7-216.e13
Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61
Molinuevo, José L; Cami, Jordi; Carné, Xavier et al. (2016) Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimers Dement 12:614-22
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Suárez-Calvet, Marc; Araque Caballero, Miguel Ángel; Kleinberger, Gernot et al. (2016) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8:369ra178

Showing the most recent 10 out of 83 publications